Retinal diseases include a number of eye conditions that are typically secondary to age-related systemic diseases, such as cardiovascular disease, diabetes, auto-immune disorders, etc. The most prevalent diseases include dry and wet age-related macular degeneration, diabetic macular oedema, diabetic retinopathy, retinal vein occlusion, cystoid macular oedema and uveitis. These conditions are typically chronic or recurring and can present as early as age 40.
Our drug administration technology enables routine administration to deliver drugs to specific back-of-eye tissues, including the suprachoroidal, sub-retinal and other small spaces. Our approach improves both therapeutic benefits and safety.
Our drug formulations are designed to suit the unique ocular environments into which they are delivered, resulting in optimised pharmacokinetics (drug movement) and pharmacodynamics (therapeutic effect) as well clinical effects lasting up to twelve months in duration.
Our product development pipeline includes treatments for both prevalent retinal diseases, such as age-related macular degeneration and diabetic macular oedema, as well as rare and orphan conditions.